Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies

Vaccine

Volumn 28, Issue 37, 2010, Pages 6065-6075

  Ramirez, Karina ^a   Ditamo, Yanina ^a   Galen, James E ^a   Baillie, Les W J ^b   Pasetti, Marcela F ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anthrax vaccines; Newborn mice; Prime boost immunization; S. Typhi live vectors

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; TY21A PROTECTIVE ANTIGEN; TYPHOID VACCINE; UNCLASSIFIED DRUG; ALUMINUM POTASSIUM SULFATE; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN A; LIVE VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNIZATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; FEMALE; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; PASSIVE IMMUNIZATION; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI;

ADMINISTRATION, INTRANASAL; ALUM COMPOUNDS; ANIMALS; ANIMALS, NEWBORN; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIAL TOXINS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; SALMONELLA TYPHI; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 77955518755     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.089     Document Type: Article

References (54)

1. Knight J. Delivering death in the mail. Nature 2001, 414(December (6866)):837-838.
2. Baillie L.W. Is new always better than old?: the development of human vaccines for anthrax. Hum Vaccine 2009, 5(December (12)).
3. Emergent, BioSolutions., BioThrax (Anthrax Vaccine, Adsorbed), Product Prescribing, Information, 2010. p. 1-16. http://www.emergentbiosolutions.com/pdf/emergent_biothrax_us.pdf.
4. Cybulski R., Sanz P., O'Brien A.D. Anthrax vaccination strategies. Mol Aspects Med 2009, 30(December (6)):490-502.
5. Bienek D.R., Loomis L.J., Biagini R.E. The anthrax vaccine: no new tricks for an old dog. Hum Vaccine 2009, 5(March (3)):184-189.
6. Nass M. The anthrax vaccine program: an analysis of the CDC's recommendations for vaccine use. Am J Public Health 2002, 92(May (5)):715-721.
7. Fowler G.L., Baggs J.M., Weintraub E.S., Martin S.W., McNeil M.M., Gust D.A. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program. Pharmacoepidemiol Drug Saf 2006, 15(December (12)):880-888.
8. Ryan M.A., Smith T.C., Sevick C.J., Honner W.K., Loach R.A., Moore C.A., et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008, 168(August (4)):434-442.
9. Ready T. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat Med 2004, 10(February (2)):112.
10. Cheung D.T., Kam K.M., Hau K.L., Au T.K., Marston C.K., Gee J.E., et al. Characterization of a Bacillus anthracis isolate causing a rare case of fatal anthrax in a 2-year-old boy from Hong Kong. J Clin Microbiol 2005, 43(April (4)):1992-1994.
11. Freedman A., Afonja O., Chang M.W., Mostashari F., Blaser M., Perez-Perez G., et al. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA 2002, 287(February (7)):869-874.
12. Phipps A.J., Premanandan C., Barnewall R.E., Lairmore M.D. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev 2004, 68(December (4)):617-629.
13. Grabenstein J.D. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008, 46(January (1)):129-136.
14. Capozzo A.V., Cuberos L., Levine M.M., Pasetti M.F. Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect Immun 2004, 72(August (8)):4637-4646.
15. Ramirez K., Capozzo A.V., Lloyd S.A., Sztein M.B., Nataro J.P., Pasetti M.F. Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. J Immunol 2009, 182(January (2)):1211-1222.
16. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(October Suppl. (2)):S22-S27.
17. Black R.E., Levine M.M., Ferreccio C., Clements M.L., Lanata C., Rooney J., et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990, 8:81-84.
18. Murphy J.R., Grez L., Schlesinger L., Ferreccio C., Baqar S., Muñoz C., et al. Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect Immun 1991, 59(11):4291-4293.
19. Cryz S.J., Vanprapar N., Thisyakorn U., Olanratmanee T., Losonsky G., Levine M.M., et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993, 61(March (3)):1149-1151.
20. Olanratmanee T., Levine M., Losonsky G., Thisyakorn V., Cryz S.J. Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4-6-year-old Thai children. J Infect Dis 1992, 166(August (2)):451-452.
21. Galen J.E., Chinchilla M., Pasetti M.F., Wang J.Y., Zhao L., Arciniega-Martinez I., et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 2009, 199(February (3)):326-335.
22. Siegrist C.A. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007, 137(July Suppl. (1)):S4-S9.
23. Baillie L.W., Rodriguez A.L., Moore S., Atkins H.S., Feng C., Nataro J.P., et al. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy. Vaccine 2008, 26(November (48)):6083-6091.
24. Capozzo A.V., Ramirez K., Polo J.M., Ulmer J., Barry E.M., Levine M.M., et al. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol 2006, 176(May (9)):5671-5681.
25. Li H., Soroka S.D., Taylor T.H., Stamey K.L., Stinson K.W., Freeman A.E., et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008, 333(April (1-2)):89-106.
26. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004, 190(October (7)):1228-1236.
27. Kang T.J., Fenton M.J., Weiner M.A., Hibbs S., Basu S., Baillie L., et al. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect Immun 2005, 73(November (11)):7495-7501.
28. Stokes M.G., Titball R.W., Neeson B.N., Galen J.E., Walker N.J., Stagg A.J., et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 2007, 75(April (4)):1827-1834.
29. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 2005, 73(June (6)):3408-3414.
30. Vindurampulle C.J., Cuberos L.F., Barry E.M., Pasetti M.F., Levine M.M. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine 2004, 22(September (27-28)):3744-3750.
31. Van de P.P. Transfer of antibody via mother's milk. Vaccine 2003, 21(July (24)):3374-3376.
32. Klinman D.M., Currie D., Lee G., Grippe V., Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect 2007, 9(October (12-13)):1478-1483.
33. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003, 170(June (11)):5636-5643.
34. Flick-Smith H.C., Eyles J.E., Hebdon R., Waters E.L., Beedham R.J., Stagg T.J., et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 2002, 70(April (4)):2022-2028.
35. Sloat B.R., Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 2006, 23(February (2)):262-269.
36. Welkos S., Little S., Friedlander A., Fritz D., Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001, 147(June (Pt 6)):1677-1685.
37. Guidi-Rontani C., Levy M., Ohayon H., Mock M. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol 2001, 42(November (4)):931-938.
38. Welkos S., Friedlander A., Weeks S., Little S., Mendelson I. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol 2002, 51(October (10)):821-831.
39. Glomski I.J., Corre J.P., Mock M., Goossens P.L. Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J Immunol 2007, 178(March (5)):2646-2650.
40. Ingram R.J., Metan G., Maillere B., Doganay M., Ozkul Y., Kim L.U., et al. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encopassing infection-specific epitopes. J. Immunol. 2010, 184(April (7)):3814-3821.
41. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007, 75(August (8)):4020-4029.
42. Zeng M., Xu Q., Pichichero M.E. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine 2007, 25(May (18)):3588-3594.
43. Ngoc P.L., Gold D.R., Tzianabos A.O., Weiss S.T., Celedon J.C. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol 2005, 5(April (2)):161-166.
44. Tross D., Klinman D.M. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J Immunol 2008, 181(October (8)):5785-5790.
45. Ota M.O., Vekemans J., Schlegel-Haueter S.E., Fielding K., Sanneh M., Kidd M., et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002, 168(January (2)):919-925.
46. Kolla R.V., Chintalapati S., Sabet M., Santelli E., Liddington R.C., David M., et al. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS One 2007, 2(10):e1044.
47. Abboud N., Casadevall A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol 2008, 15(July (7)):1115-1123.
48. Osorio M., Wu Y., Singh S., Merkel T.J., Bhattacharyya S., Blake M.S., et al. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect Immun 2009, 77(April (4)):1475-1482.
49. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21(July (24)):3406-3412.
50. Siegrist C.A., Cordova M., Brandt C., Barrios C., Berney M., Tougne C., et al. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine 1998, 16(August (14-15)):1409-1414.
51. Downing J., Greig T.W., Quattlebaum M.D., Valentin M., Heeren T.C., Grabenstein J.D. Assessing the safety of anthrax immunization in US Army aircrew members via physical examination. J Occup Environ Med 2007, 49(October (10)):1079-1085.
52. Siegrist C.A., Barrios C., Martinez X., Brandt C., Berney M., Córdova M., et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 1998, 28(December (12)):4138-4148.
53. Gunn B.M., Wanda S.Y., Burshell D., Wang C., Curtiss R. Construction of recombinant attenuated Salmonella enterica Typhimurium vaccine (RASV) vector strains for safety in newborn and infant mice. Clin Vaccine Immunol 2010.
54. Galen J.E., Wang J.Y., Chinchilla M., Vindurampulle C., Vogel J.E., Levy H., et al. A new generation of stable, non-antibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect Immun 2010, 78(January (1)):337-347.